Your browser is no longer supported. Please, upgrade your browser.
ASND Ascendis Pharma A/S daily Stock Chart
ASND [NASD]
Ascendis Pharma A/S
Index- P/E- EPS (ttm)-6.50 Insider Own1.36% Shs Outstand48.21M Perf Week2.89%
Market Cap8.62B Forward P/E- EPS next Y-5.81 Insider Trans0.00% Shs Float6.00M Perf Month6.28%
Income-311.60M PEG- EPS next Q-1.58 Inst Own98.50% Short Float31.82% Perf Quarter19.18%
Sales9.90M P/S870.25 EPS this Y-48.00% Inst Trans6.51% Short Ratio11.73 Perf Half Y27.77%
Book/sh11.70 P/B14.02 EPS next Y9.00% ROA-40.70% Target Price181.49 Perf Year50.34%
Cash/sh10.61 P/C15.46 EPS next 5Y24.00% ROE-46.20% 52W Range92.00 - 168.56 Perf YTD17.89%
Dividend- P/FCF- EPS past 5Y-61.90% ROI-35.70% 52W High-2.70% Beta0.88
Dividend %- Quick Ratio9.00 Sales past 5Y-0.90% Gross Margin- 52W Low78.27% ATR5.21
Employees330 Current Ratio9.00 Sales Q/Q-56.30% Oper. Margin- RSI (14)63.25 Volatility4.13% 2.99%
OptionableYes Debt/Eq0.07 EPS Q/Q-57.80% Profit Margin- Rel Volume0.89 Prev Close161.06
ShortableYes LT Debt/Eq0.06 EarningsAug 27 AMC Payout- Avg Volume162.72K Price164.01
Recom1.50 SMA202.85% SMA509.00% SMA20017.76% Volume144,387 Change1.83%
Sep-14-20Resumed JP Morgan Overweight $160
Mar-20-20Initiated Oppenheimer Outperform $199
Oct-11-19Initiated Morgan Stanley Overweight $128
Mar-25-19Initiated Evercore ISI Outperform
Jan-24-19Upgrade Leerink Partners Mkt Perform → Outperform
Jan-24-19Initiated Cantor Fitzgerald Overweight $102
Jun-26-18Initiated Stifel Buy $85
Apr-02-18Reiterated Leerink Partners Mkt Perform $37 → $64
May-11-17Initiated JP Morgan Overweight $36
Mar-09-17Downgrade Leerink Partners Outperform → Mkt Perform
Feb-09-17Initiated Credit Suisse Outperform $28
Sep-26-16Initiated Wedbush Outperform $34
Oct-23-20 08:05AM  
Oct-21-20 05:51PM  
Oct-08-20 06:40PM  
Sep-29-20 11:04AM  
Sep-28-20 07:00PM  
Sep-23-20 04:05PM  
Sep-15-20 05:45PM  
08:30AM  
Sep-11-20 07:05AM  
Sep-10-20 07:05AM  
Sep-08-20 04:44PM  
Sep-04-20 08:30AM  
07:05AM  
Sep-02-20 04:05PM  
Aug-27-20 10:00PM  
04:24PM  
04:01PM  
Aug-21-20 09:48AM  
Aug-13-20 04:01PM  
12:48PM  
Aug-12-20 07:05AM  
Aug-04-20 08:30AM  
Jul-24-20 09:47AM  
Jul-10-20 08:49PM  
Jul-07-20 10:11PM  
Jul-06-20 12:58PM  
09:25AM  
Jun-29-20 11:44AM  
Jun-26-20 08:29AM  
Jun-22-20 08:30AM  
Jun-10-20 12:27PM  
Jun-08-20 08:15AM  
Jun-03-20 03:46PM  
May-29-20 09:28PM  
May-22-20 06:14AM  
May-19-20 04:01PM  
02:30PM  
May-11-20 08:30AM  
May-08-20 11:46AM  
May-07-20 04:01PM  
Apr-21-20 06:01AM  
Apr-19-20 04:00PM  
Apr-16-20 09:40PM  
Apr-15-20 04:58PM  
Apr-01-20 04:01PM  
Mar-25-20 04:01PM  
Mar-22-20 08:25PM  
Mar-21-20 08:49AM  
Mar-17-20 12:00PM  
Feb-12-20 04:01PM  
Feb-10-20 09:28AM  
Feb-06-20 10:44AM  
Feb-04-20 11:28AM  
Jan-21-20 05:21AM  
Jan-12-20 07:45PM  
Jan-09-20 04:00PM  
Dec-26-19 11:26AM  
Dec-06-19 11:57PM  
Dec-04-19 12:42PM  
Nov-22-19 05:38AM  
Nov-21-19 09:05AM  
Nov-18-19 04:01PM  
10:33AM  
01:02AM  
Nov-14-19 04:01PM  
Nov-12-19 09:52AM  
Nov-11-19 07:50AM  
Nov-08-19 04:02PM  
Nov-06-19 04:02PM  
Nov-05-19 11:50AM  
11:13AM  
Nov-04-19 06:30PM  
Oct-29-19 09:00AM  
Oct-24-19 11:47AM  
Oct-21-19 04:04PM  
Oct-14-19 08:44PM  
Oct-01-19 03:50PM  
Sep-26-19 08:25AM  
Sep-19-19 08:30AM  
Sep-12-19 04:20PM  
Sep-03-19 03:20AM  
Aug-29-19 05:15PM  
04:23AM  
Aug-28-19 04:01PM  
Aug-14-19 05:30PM  
Jul-18-19 04:12PM  
Jun-19-19 08:30AM  
Jun-10-19 10:10AM  
May-31-19 02:02AM  
May-30-19 04:02PM  
02:30PM  
May-20-19 07:30AM  
May-16-19 08:00AM  
May-07-19 04:02PM  
12:43PM  
May-06-19 11:09AM  
Apr-29-19 09:28AM  
Apr-27-19 08:40AM  
Apr-24-19 05:26PM  
Apr-23-19 08:59AM  
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.